Objective. To assess changes in antibiotic resistance of eight of the World Health Organization priority bug-drug combinations and consumption of six antibiotics (ceftriaxone, cefepime, piperacillin/tazobactam, meropenem, ciprofloxacin, vancomycin) before (March 2018 to July 2019) and during (March 2020 to July 2021) the COVID-19 pandemic in 31 hospitals in Valle del Cauca, Colombia. Methods. This was a before/after study using routinely collected data. For antibiotic consumption, daily defined doses (DDD) per 100 bed-days were compared. Results. There were 23 405 priority bacterial isolates with data on antibiotic resistance. The total number of isolates increased from 9 774 to 13 631 in the periods before and during the pandemic, respectively. While resistance significantly decreased for four selected bug-drug combinations (Klebsiella pneumoniae, extended spectrum beta lactamase [ESBL]-producing, 32% to 24%; K. pneumoniae, carbapenem-resistant, 4% to 2%; Pseudomonas aeruginosa, carbapenem-resistant, 12% to 8%; Acinetobacter baumannii, carbapenem-resistant, 23% to 9%), the level of resistance for Enterococcus faecium to vancomycin significantly increased (42% to 57%). There was no change in resistance for the remaining three combinations (Staphylococcus aureus, methicillin-resistant; Escherichia coli, ESBL-producing; E. coli, carbapenem-resistant). Consumption of all antibiotics increased. However, meropenem consumption decreased in intensive care unit settings (8.2 to 7.1 DDD per 100 bed-days). Conclusions. While the consumption of antibiotics increased, a decrease in antibiotic resistance of four bug-drug combinations was observed during the pandemic. This was possibly due to an increase in community-acquired infections. Increasing resistance of E. faecium to vancomycin must be monitored. The findings of this study are essential to inform stewardship programs in hospital settings of Colombia and similar contexts elsewhere.
We used a detailed dengue classification to assess the variability in disease severity and outcomes in a cohort of patients classified as “dengue with warning signs” according to the 2009 World Health Organization (WHO) criteria. We describe a wide range of severity and outcomes, which highlights the need and potential to improve the current WHO dengue classification.
1 December 2012 in Revista chilena de infectología
Neutropenia is one of the most common complications in children with cancer, and it's the most important parameter to determine infection risk. In neutropenic patients the signs and symptoms could be scarce and in occasions fever could be the only symptom. For these reasons all patients with febrile neutropenia (FN) should be considered as if they had a possibly severe disease. To describe the clinical characteristics and laboratory parameters observed in cancer patients with FN attended at our hospital to perform a more rational management of this complication in the future. The clinical files accumulated during 36 months, belonging to patients aged 0 to 15 years that were hospitalized because of cancer and FN were reviewed. In this series the source of fever was found in 48.6% of 105 NF episodes, and bacteria were isolated from blood or urine culture in 38%. The most frequent bacterial species recovered were methicillin susceptible S. aureus (20.8%) and ESBL negative E. coli (20.8%). Piperacillin/tazobactam was the most used first line antibiotic prescribed (87.6%) and meropenem was the second choice (18%). Granulocyte colony stimulating factor was used in 61.9% of the cases and episodes mortality rate was 6.7%. Clinical characteristics and bacteriological findings in our institution do not differ significantly from what has been described for pediatric cancer patients in other series.
11 October 2023 in Case Reports in Infectious Diseases
Background. Adverse events after vaccination against COVID-19 include rare events, such as GuillainBarr syndrome. Study Aims. Documentation of clinical and temporary characteristics of the GuillainBarr syndrome after using anti-COVID-19 ChAdOx1 nCoV-19 vaccine. Case Presentation. An adult, 29-year-old male, without relevant medical history, who developed neuromuscular symptoms nine days after administration of the first dose of anti-COVID-19 ChAdOx1 nCoV-19 vaccine. Results. Symptoms appeared nine days after vaccination, with lower limbs paresthesia. Three days later, paresthesia of upper limbs occurred. The following day, distal weakness of limbs, with standing and gripping difficulties, occurred. The clinical evaluation demonstrated dysarthria, incomplete palpebral closure, bilateral facial, and tongue paresis. The electromyography was compatible with a motor demyelinating polyneuropathy, confirming the diagnosis of the GuillainBarr syndrome. Management with five sessions of plasma exchange was prescribed, with favorable clinical results. Conclusions. Clinical and laboratory tests confirmed the GuillainBarr syndrome and the time elapsed from the date of the vaccine administration to the appearance of initial symptoms, added to the absence of other causes, and allowed to establish that the disease was caused by the vaccination.
Lymphadenopathy is a common cause for medical consultation in the child population, accounting for up to 44% in children under 5 years old. In some cases, it is required to take lymph node biopsy specimens in order to clarify the diagnosis. To describe the clinical and histological features of paediatric patients with lymphadenopathy and lymph node biopsies. Descriptive and retrospective study conducted in Medellin (Colombia) in a fourth-level hospital between January 1st of 2009 and December 31st of 2012. In the study, lymph node biopsy specimens were taken from children under 15 years old. Demographic, clinical and laboratory features, and characteristics of the patients were evaluated, as well as the histopathological diagnosis of the lymph node biopsies. From the child population, 61 children met the eligibility criteria and 33 (54.1%) of them were male with an average age of 6 years old. The most common pathological diagnoses in the study group were as follows: reactive hyperplasia (50.8%), neoplasms (27.9%), chronic granulomatous disease (4.9%), and bacterial infection (3.3%). It could be concluded from the findings in the study that Hodgkin lymphoma is very common among the neoplastic diseases, with 18%, and the most frequent location was the neck with 60.6%. This study demonstrates the importance of performing a differential diagnosis when approaching patients with lymphadenopathy. As reported in the world medical literature, benign origin is the most common cause of lymphadenopathy in children.
Introducción: Las guías de práctica clínica (GPC) disponibles sobre infección latente por tuberculosis (ILTB) no son exclusivas de población pediátrica. Objetivo: Desarrollar recomendaciones basadas en evidencia para evaluación, tratamiento y seguimiento de niños contacto de pacientes con tuberculosis (TB) pulmonar en Colombia Métodos: Conformamos un grupo desarrollador multidisciplinario (expertos clínicos, de campo, investigadores, y metodólogos), representante de pacientes y tomadores de decisión. Construimos 10 preguntas y priorizamos desenlaces sobre diagnóstico (evaluación clínica, radiografía de tórax y pruebas de liberación de interferón gamma-IGRA), tratamiento (eficacia de regímenes en distinos escenarios) y seguimiento (monitoreo y estrategias para incrementar adherencia) del niño con ILTB. Realizamos revisiones sistemáticas de literatura para identificar guías, revisiones de literatura y estudios primarios. Evaluamos calidad y riesgos de sesgos de estos con herramientas específicas. Sintetizamos la evidencia de forma narrativa, y en algunos casos con metanálisis de novo (diagnósticos y en red). Evaluamos la certeza de la evidencia con sistema GRADE. Utilizamos el marco de la evidencia a la recomendación de GRADE para guiar el proceso de recomendaciones. Resultados: El grupo recomienda el uso de radiografía, y prueba de IGRA en niños contacto para identificar tubercolosis activa. Recomendamos regímenes cortos en lugar de largos en niños con y sin inmunosupresión y regímenes guiados según susceptibilidad en casos de contacto con TB resistente. Recomendamos seguimiento clínico mensual y la implementación de abordajes integrales para identificar las barreras para incentivar la adherencia al tratamiento. Conclusiones: El grupo aporta recomendaciones basadas en la evidencia contextualizadas para los niños con ILTB en Colombia.